TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Erection Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male subjects aged 18-55~* Documented clinical diagnosis of erectile dysfunction confirmed by an IIEF-EF Domain score of less than or equal to 25. (If the subject scores greater than 25 on the IIEF-EF Domain, screening procedures should be terminated.)~Exclusion Criteria:~* Subjects who have been treated with more than 6 doses of sildenafil citrate or any other phosphodiesterase type 5 (PDE-5) inhibitor such as vardenafil or tadalafil for erectile dysfunction \[Note: subjects should not have taken any PDE-5 inhibitors within 4 weeks prior to the date of screening\]

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Port Wine Stain birthmark~* Male and female subjects of any age who are in good health.~* Fitzpatrick skin type I-VI~Exclusion Criteria:~* Pregnant or lactating~* History of cutaneous photosensitivity~* History of hypersensitivity to imiquimod 5% cream or any of its components~* History of photodermatoses

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imiquimod (Type: EXPERIMENTAL): Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
- Placebo (Type: PLACEBO_COMPARATOR): Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or non-pregnant, non-lactating female ≥ 18 years of age.~* Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin).~* Provisionally confirmed at baseline by a positive potassium hydroxide (KOH) wet mount preparation~* Total score ≥ 4 for the clinical signs and symptoms of tinea pedis in the target area. In addition the target area must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for either pruritus or scaling.~Exclusion Criteria:~* Presence of any other infection of the foot or other disease process that, in the Investigator's opinion, may interfere with the evaluation of the patient's tinea pedis~* History of or current psoriasis, Lichen planus or contact dermatitis involving the feet within the previous 12 months.~* Past history of dermatophyte infections with a lack of response to antifungal therapy~* Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface or onychomycosis involving ≥ 20% of the area of either great toenail and/or involving more than five toenails in total or other concurrent dermatophytoses (e.g., tinea cruris) and any other skin disease to an extent that, in the opinion of the investigator, might interfere with the evaluation of tinea pedis or study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test (Type: EXPERIMENTAL): Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
- Reference Standard (Type: ACTIVE_COMPARATOR): Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in New Onset Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 8 and 45 years~* Within 3 months of diagnosis of type 1 diabetes~* Have presence of at least one diabetes-related autoantibody~* Must have stimulated C-peptide levels of at least 0.2 pmol/ml measured during a mixed meal tolerance test (MMTT) within one month of randomization~* If female with reproductive potential, willing to avoid pregnancy and undergo pregnancy testing while participating in the study~* Have not received an immunization for at least one month~* Must be willing to comply with intensive diabetes management~* Must weigh at least 25 kg at study entry~Exclusion Criteria:~* Are immunodeficient or have clinically significant chronic lymphopenia~* Have an active infection or positive purified protein derivative (PPD) test result~* Currently pregnant or lactating; or anticipate becoming pregnant.~* Require chronic use of steroids~* Have current or past HIV, hepatitis B, or hepatitis C infection~* Have any complicating medical issues that interfere with study conduct or cause increased risk~* Have a history of malignancies~* Currently using non-insulin pharmaceuticals that effect glycemic control~* Currently participating in another type 1 diabetes treatment study

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab Intravenous Infusion (Type: EXPERIMENTAL): Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
- Placebo Intravenous Infusion (Type: PLACEBO_COMPARATOR): Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Naturally or surgically postmenopausal women, with or without an intact uterus, aged 50 to 75 years of age, inclusive. FSH levels greater than 40 mIU/mL~Exclusion Criteria:~1. Currently taking any estrogen/progesterone hormone replacement therapy (HRT).~2. History of allergy or sensitivity to hydroxyprogesterone caproate, castor oil or any of the constituents of the study medications, or history of any drug hypersensitivity or intolerance~3. Poorly controlled diabetes.~4. History or current evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic disease (e.g., stroke, myocardial infarction).~5. Known, suspected, or current history of carcinoma of the breast.~6. Subjects with a past history of breast cancer on aromatase inhibitors or selective estrogen receptor modulators.~7. Known, suspected, or current history of hormone dependent tumor within the last 5 years.~8. Any current or recent (within previous 12 months) genital bleeding of unknown etiology.~9. Receipt of any investigational drug within 30 days.~10. Receipt of any prescription or OTC medications that are known to alter CYP3A4 or CYP3A5 levels (e.g., carbamazepine, St. John's Wort, ketoconazole, rifampin, ritonavir, alprazolam, azithromycin, loratadine, etc.) within 14.~11. Any estrogen, progestin, or selective estrogen receptor modulator (SERM) treatment within specified time windows before the study start, ranging from 2 to 6 months.~12. High blood pressure at the screening evaluation, defined as systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg.~13. History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months.~14. Use of tobacco products within 30 days of the start of the study.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Subcutaneous (SQ) injection using an autoinjector
- Treatment B (Type: ACTIVE_COMPARATOR): Intramuscular injection (IM) using syringe and needle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients affected by clinical diagnosis of reflex syncope who meet all the following criteria:~* age \>=40 years~* significant limitation of social and working life due to unpredictable or frequent syncope recurrences, ≥2 within the last year.~* type 2B cardio-inhibitory response to TT (according to the VASIS classification).~* Alternative therapies have failed or were not feasible.~* exclusion of other possible competitive causes of syncope.~Exclusion Criteria:~- Any other indication to IPG, implantable defibrillator (ICD), cardiac resynchronization therapy (CRT), according to current guidelines~Any cardiac dysfunctions possibly leading to loss of consciousness:~* overt heart failure;~* ejection fraction (LVEF) \<40% (Echo-assessed within 3-month prior to study participation);~* myocardial infarction;~* diagnosis of hypertrophic or dilated cardiomyopathy;~* clinically significant valvular disease;~* sinus bradycardia \<50 bpm or sinoatrial block;~* Mobitz I second-degree atrioventricular block;~* Mobitz II second or third-degree atrioventricular block;~* bundle-branch block;~* rapid paroxysmal supraventricular tachycardia or ventricular tachycardia;~* preexcited QRS complexes;~* prolonged QT interval;~* Brugada syndrome;~* arrhythmogenic right ventricular cardiomyopathy~* Symptomatic orthostatic hypotension diagnosed by standing BP measurement;~* Nonsyncopal loss of consciousness (eg, epilepsy, psychiatric, metabolic, drop-attack, cerebral transient ischemic attack, intoxication, cataplexy).~* Symptomatic cardioinhibitory carotid sinus hypersensitivity.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DDD+CLS (Type: EXPERIMENTAL): The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
- ODO (Type: PLACEBO_COMPARATOR): The pacemaker will be programmed in ODO mode.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. MDS with WHO classification of RA, RARS, RCMD-RS, RCUD, and RCMD and RAEB-1 (all subtypes of MDS with the exception of RAEB 2, CMML, and MDS/MPN overlap)~ 2. Anemia requiring transfusion support with at least one unit of packed red blood cells per month for greater than or equal to 2 months~     OR~     Anemia (hemoglobin less than 9 or a reticulocyte count less than 60,000)~     OR~     thrombocytopenia (platelet count less than 50000/ul)~     OR~     neutropenia (absolute neutrophil count less than 500/ul).~ 3. Off all other treatments for MDS (except filgrastim (G-CSF), erythropoietin, and transfusion support and related medications) for at least four weeks. Filgrastim (G-CSF) can be used before, during and after the protocol treatment for patients with documented neutropenia (less than 500/Ul) as long as they meet the criteria for anemia and/or thrombocytopenia as stated above.~ 4. Ages 18-72 (inclusive)~EXCLUSION CRITERIA:~1. Chronic myelomonocytic leukemia (CMML), MDS/MPN overlap, WHO RAEB-2~2. Secondary MDS~3. Failure to respond to prior therapy with ATG or ATG/CsA~4. Prior therapy with combination chemotherapy~5. Transformation to acute leukemia (FAB sub-group RAEB-T, i.e., greater than 20% blasts in marrow aspirate)~6. Failure to discontinue the herbal supplements Echinacea purpurea or Usnea barbata (Old Man's Beard) within 2 weeks of enrollment.~7. Active infection not adequately responding to appropriate therapy~8. HIV positive patients~9. Active malignant disease (excluding non-melanoma skin carcinoma)~10. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy or that death within 7-10 days is likely.~11. Life expectancy less than 6 months~12. Low predicted probability of response~13. Previous hypersensitivity to alemtuzumab (Campath\[R\]) or its components~14. Current pregnancy, or unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~15. Not able to understand the investigational nature of the study or give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab (Type: EXPERIMENTAL): Patients received a 1-mg test dose of alemtuzumab, and the following day, alemtuzumab was administered at 10 mg/dose intravenously for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily signed informed consent to participate in the study;~* Chronic AD, according to American Academy of Dermatology Consensus Criteria or the local diagnostic criteria, that has been present for at least 1 year before screening;~* EASI score ≥16 at screening and baseline;~* IGA score ≥3 (moderate) at both screening and baseline;~* BSA ≥10% at both screening and baseline;~* Documented recent history (within 1 year prior to screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks).~Exclusion Criteria:~* Current or past history of clinically significant illness(es) deemed by the Investigator to be likely to affect the study conduct and assessments. Examples include, but are not limited to, clinically significant cardiovascular (e.g., New York Heart Association \[NYHA\] Class III or IV), uncontrolled diabetes (HbA1c ≥9%), liver (e.g., Child-Pugh class B or C), renal, respiratory, hematologic, central nervous system, psychiatric, or autoimmune diseases/disorders;~* Any of the following laboratory abnormalities at screening:~  * Serum creatinine: \>1.5 mg/dL~ * AST or ALT: ≥2.5 times the upper limit of normal (ULN)~ * Neutrophil count: \<1.5×10³/μL~ * Other laboratory abnormalities that may affect the completion or evaluation of the study, as judged by the Investigator;~* Active malignancies, or onset or a history of treatment of malignancies within 5 years prior to informed consent (except curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: PLACEBO_COMPARATOR): Subcutaneous administration of placebo
- Arm B (Type: EXPERIMENTAL): Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
- Arm C (Type: EXPERIMENTAL): Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
- Arm D (Type: EXPERIMENTAL): Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
- Arm E (Type: EXPERIMENTAL): Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted with renal dysfunction (baseline serum creatinine level above the upper limit of normal of the serum creatinine \[\>93umol/l for women and \>117umol/l for men\] or GFR \<60ml/min \[GFR calculated using the abbreviated MDRD study equation\]) scheduled to undergo an intraarterial or intravenous radiographic contrast procedure within the next 24 hours.~Exclusion Criteria:~* Age \<18 years~* Preexisting dialysis~* Allergy to radiographic contrast~* Pregnancy (women \< 50 years: pregnancy test required)~* Severe heart failure (New York Heart Association \[NYHA\] III-IV)~* N-acetylcysteine \</= 24 hours before contrast~* Clinically vulnerable condition requiring continuous fluid therapy e.g. severe sepsis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
- 2 (Type: ACTIVE_COMPARATOR): 7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
- 3 (Type: ACTIVE_COMPARATOR): short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active rheumatoid arthritis (RA) diagnosed after the age of 16~* Currently taking methotrexate~* 6 or more swollen joints and 6 or more tender/painful joints (from 28 joint count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more~* At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)~Exclusion Criteria:~* Females who are pregnant or breast feeding~* Poorly controlled hypertension~* Liver disease or significant liver function test abnormalities~* Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders~* Recent or significant cardiovascular disease~* Significant active or recent infection including tuberculosis~* Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment with other biological agent~* Severe renal impairment~* Neutropenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing Regimen A (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen B (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen C (Type: PLACEBO_COMPARATOR): Oral Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete